SAN DIEGO, Sept. 27, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data on rezafungin clinical safety and pharmacokinetics in people with hepatic impairment, at IDWeek taking place virtually from September 29-October 3, 2021. Rezafungin is a novel once-weekly echinocandin currently…

SAN DIEGO, Sept. 07, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care for prevention and treatment of serious diseases, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference and Cantor Global Healthcare Conference. H.C. Wainwright 23rd Annual Global Investment ConferenceCidara's presentation will be available on-demand beginning…

Virtual event will highlight the broad potential of the Cloudbreak® platform and the commercial potential for rezafungin Clinical thought leaders will highlight the risks of invasive fungal infections in cancer patients, and the unmet medical need in respiratory viral diseases Webinar to be held on Tuesday, September 21st at 10:00am ET SAN DIEGO, Sept. 02, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting compounds designed to transform the standard of care…

Appointments add two biotech industry veterans each with over two decades of experience to Company's management teamSAN DIEGO, Sept. 01, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of Preetam Shah, Ph.D., MBA, as chief financial officer and chief business officer, and Shane Ward as chief legal officer and corporate secretary.…

Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. The trial includes 184 patients diagnosed with candidemia and/or invasive…

SAN DIEGO, Aug. 12, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its corporate activities and product pipeline. "We began the quarter with the announcement of our worldwide license and collaboration agreement with Janssen for the development and…

SAN DIEGO, Aug. 05, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021. Panel Information:Date:Wednesday, August 11, 2021Time:4:40 PM ETWebcast: A live audio webcast and replay of…

SAN DIEGO, July 27, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International…

Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care Three additional presentations to highlight areas of unmet medical needs to improve treatment of candidemia and invasive candidiasis SAN DIEGO, July 12, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing…

SAN DIEGO, July 07, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 172,000 shares of its common stock to eight new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive…